Sold as Antepar, Multifuge, Bryrel. Every FDA application for this active ingredient: 3 branded and 5 generic.
As of Nov 16, 2026, FDA lists 8 applications for Piperazine Citrate (sold as Antepar, Multifuge, Bryrel), first approved Jul 12, 1954, with 0 new uses approved and 0 published complete response letters.
| Jul 12, 1954 | MultifugeNDA 9452 · New formulation or manufacturer | Bluline | 0 | Discontinued |
| Jan 25, 1957 | AnteparNDA 9102 · New active ingredient | Glaxosmithkline | 1 | Discontinued |
| Jul 19, 1973 | Piperazine CitrateANDA 80874 | Impax Labs | 2 | Discontinued |
| Jul 25, 1974 | Piperazine CitrateANDA 80963 | Lannett | 1 | Discontinued |
| — | Piperazine CitrateANDA 80671 | Luitpold | 0 | Discontinued |
| — | Piperazine CitrateANDA 80774 | Alpharma US Pharms | 0 | Discontinued |
| — | VermidolANDA 80992 | Solvay | 0 | Discontinued |
| — | BryrelNDA 17796 | Sanofi Aventis US | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA